Molecularly-Targeted Product Candidates

We are developing biologics that target myostatin and activin, growth factors which are members of the Transforming Growth Factor-Beta, or TGF-β, protein superfamily. Myostatin and activin play roles in the growth and maintenance of muscle and many other body tissues. STM 434 is a ligand trap that targets Activin A (and other related factors) and is being studied in a Phase 1 clinical study in patients with ovarian cancer and other solid tumors.